Mike Johnson defends Trump’s ‘sedition’ attacks on Democrats

As the Senate adjourns for Thanksgiving without a bipartisan fix for expiring Affordable Care Act premium tax credits, Democrats are demanding a clean extension of the subsidies that expire next month and have rejected Sen. Bill Cassidy’s proposal to redirect funds into health savings accounts as effectively privatizing coverage and unlikely to blunt premium spikes; several Republicans now acknowledge major policy changes are unlikely before Dec. 31, increasing the odds of a standalone extension vote but also leaving room for a future reconciliation push. At the same time Senate Finance Chair Mike Crapo and ranking member Ron Wyden are advancing bipartisan legislation to rein in pharmacy benefit managers—potentially by year-end or early January—which market participants should watch for its implications on drug pricing and payer/provider margins. Other congressional priorities investors should monitor include permitting reform negotiations and a fast-moving National Defense Authorization Act deadline when lawmakers return from recess.

Analysis

The Senate adjourned for Thanksgiving without a bipartisan solution to expiring Affordable Care Act premium tax credits, which the article says expire next month, leaving Democrats demanding a clean extension and rejecting Sen. Bill Cassidy’s proposal to redirect funds into health savings accounts; Senate Minority Leader Chuck Schumer characterized that plan as effectively privatizing coverage and health experts told reporters it would not necessarily blunt looming premium spikes. Several Republicans, including Rep. Don Bacon and Sen. Lisa Murkowski, conceded major policy changes are unlikely before the Dec. 31 deadline, increasing the probability of a near-term standalone vote to extend credits but also preserving the option of a future, partisan reconciliation push that Senate Budget Chair Lindsey Graham signaled he intends to pursue likely next year. Senate Finance Chair Mike Crapo and ranking member Ron Wyden are advancing bipartisan legislation targeting pharmacy benefit managers, with Wyden hopeful of Senate action by year-end and a committee having approved a PBM bill 26-0 in 2023; aides say the package could travel on a must-pass vehicle or resurface in January. Investors should also watch ancillary near-term congressional items cited in the article — a House permitting reform markup and an NDAA compromise expected for an early-December floor vote — as additional policy catalysts for affected sectors.

Key Decisions for Investors

• Monitor the timing and outcome of the promised standalone ACA extension vote next month and avoid making large directional bets on insurers or exchange-centric names until subsidy clarity is resolved,
• Track PBM legislation closely; consider hedging or reducing exposure to pharmacy benefit managers and any payers sensitive to drug-pricing reform if the bill advances toward a must-pass vehicle,
• Watch for the NDAA text release after Thanksgiving and the early-December floor votes as a potential catalyst for defense contractors and suppliers, and maintain liquidity to respond to rapid legislative developments
• Be prepared for a policy reset in the new year if Republicans pursue reconciliation; refrain from aggressive position increases predicated on permanent legislative changes before congressional intentions are clarified